全文获取类型
收费全文 | 6557篇 |
免费 | 345篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 88篇 |
儿科学 | 170篇 |
妇产科学 | 147篇 |
基础医学 | 1330篇 |
口腔科学 | 91篇 |
临床医学 | 653篇 |
内科学 | 814篇 |
皮肤病学 | 510篇 |
神经病学 | 490篇 |
特种医学 | 394篇 |
外科学 | 1080篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 213篇 |
眼科学 | 125篇 |
药学 | 454篇 |
中国医学 | 3篇 |
肿瘤学 | 347篇 |
出版年
2021年 | 51篇 |
2019年 | 63篇 |
2018年 | 67篇 |
2016年 | 65篇 |
2015年 | 87篇 |
2014年 | 110篇 |
2013年 | 131篇 |
2012年 | 246篇 |
2011年 | 238篇 |
2010年 | 162篇 |
2009年 | 164篇 |
2008年 | 246篇 |
2007年 | 253篇 |
2006年 | 255篇 |
2005年 | 262篇 |
2004年 | 227篇 |
2003年 | 223篇 |
2002年 | 223篇 |
2001年 | 101篇 |
2000年 | 103篇 |
1999年 | 104篇 |
1998年 | 75篇 |
1997年 | 65篇 |
1996年 | 49篇 |
1995年 | 54篇 |
1994年 | 51篇 |
1992年 | 56篇 |
1991年 | 53篇 |
1989年 | 54篇 |
1988年 | 58篇 |
1985年 | 60篇 |
1984年 | 60篇 |
1982年 | 49篇 |
1977年 | 61篇 |
1939年 | 50篇 |
1933年 | 50篇 |
1932年 | 60篇 |
1931年 | 62篇 |
1930年 | 60篇 |
1929年 | 60篇 |
1928年 | 57篇 |
1927年 | 49篇 |
1926年 | 54篇 |
1925年 | 65篇 |
1924年 | 62篇 |
1923年 | 53篇 |
1921年 | 49篇 |
1914年 | 56篇 |
1913年 | 104篇 |
1912年 | 78篇 |
排序方式: 共有6924条查询结果,搜索用时 18 毫秒
121.
122.
Influence of physical activity on T1 and T2* relaxation times of healthy achilles tendons at 3T
下载免费PDF全文
![点击此处可从《Journal of magnetic resonance imaging : JMRI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
123.
124.
125.
Junctional adhesion molecule-A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Khandoga A Kessler JS Meissner H Hanschen M Corada M Motoike T Enders G Dejana E Krombach F 《Blood》2005,106(2):725-733
The endothelial receptors that control leukocyte transmigration in the postischemic liver are not identified. We investigated the role of junctional adhesion molecule-A (JAM-A), a receptor expressed in endothelial tight junctions, leukocytes, and platelets, for leukocyte transmigration during hepatic ischemia-reperfusion (I/R) in vivo. We show that JAM-A is up-regulated in hepatic venular endothelium during reperfusion. I/R-induced neutrophil transmigration was attenuated in both JAM-A-/- and endothelial JAM-A-/- mice as well as in mice treated with an anti-JAM-A antibody, whereas transmigration of T cells was JAM-A independent. Postischemic leukocyte rolling remained unaffected in JAM-A-/- and endothelial JAM-A-/- mice, whereas intravascular leukocyte adherence was increased. The extent of interactions of JAM-A-/- platelets with the postischemic endothelium was comparable with that of JAM-A+/+ platelets. The I/R-induced increase in the activity of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and sinusoidal perfusion failure was not reduced in JAM-A-/- mice, while the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-positive hepatocytes was significantly higher. Thus, we show for the first time that JAM-A is up-regulated in hepatic venules and serves as an endothelial receptor of neutrophil transmigration, but it does not mediate leukocyte rolling, adhesion, or platelet-endothelial cell interactions. JAM-A deficiency does not reduce I/R-induced microvascular and hepatocellular necrotic injury, but increases hepatocyte apoptosis, despite attenuation of neutrophil infiltration. 相似文献
126.
Stühlinger M Steinwender C Schnöll F Winter S Freihoff F Wurtz S Hintringer F 《Journal of cardiovascular electrophysiology》2008,19(3):242-246
Introduction: Radiofrequency (RF) catheter ablation targeting the slow pathway is currently the most effective treatment for patients with atrioventricular nodal reciprocating tachycardia (AVNRT). Gold exhibits a more than four times greater thermal conductivity than platinum, and the creation of deeper lesions was demonstrated in ex vivo animal experiments. The current clinical trial was initiated to compare gold catheters with standard platinum–iridium (Pt–Ir) material and to analyze differences in the increase of power or temperature as a function of time during RF ablation.
Methods: A prospective, randomized multicenter study design was used to compare RF deliveries at the slow pathway with standard Pt–Ir tip catheters (128 patients), as well as gold alloy tip electrodes (124 patients) during AVNRT ablation.
Results: Although there was a trend towards higher power delivery in the gold group (4.96 vs. 4.28 W/s), this trend was not statistically significant. Likewise, cumulative duration of all RF ablations, total procedure time, and power delivered at other time points were not significantly different between the groups. Also, the occurrence of AV-block and sensations of pain were similar in both treatment groups. However, charring on the catheter tip after the intervention was observed eightfold more frequently in the Pt–Ir group.
Conclusion: In conclusion, power delivery cannot be significantly increased by RF ablation of AVNRT with gold electrodes. But the electrode material seems to be safe and well-tolerated and specifically did not increase the risk of AV-block. The significant reduction of coagulum formation on gold tips suggests a possible advantage of this material beyond its better conduction properties. 相似文献
Methods: A prospective, randomized multicenter study design was used to compare RF deliveries at the slow pathway with standard Pt–Ir tip catheters (128 patients), as well as gold alloy tip electrodes (124 patients) during AVNRT ablation.
Results: Although there was a trend towards higher power delivery in the gold group (4.96 vs. 4.28 W/s), this trend was not statistically significant. Likewise, cumulative duration of all RF ablations, total procedure time, and power delivered at other time points were not significantly different between the groups. Also, the occurrence of AV-block and sensations of pain were similar in both treatment groups. However, charring on the catheter tip after the intervention was observed eightfold more frequently in the Pt–Ir group.
Conclusion: In conclusion, power delivery cannot be significantly increased by RF ablation of AVNRT with gold electrodes. But the electrode material seems to be safe and well-tolerated and specifically did not increase the risk of AV-block. The significant reduction of coagulum formation on gold tips suggests a possible advantage of this material beyond its better conduction properties. 相似文献
127.
Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Perry Maxwell Florinda Melendez‐Rodríguez Kyle B. Matchett Julian Aragones Nathalie Ben‐Califa Heidelinde Jaekel Ludger Hengst Herbert Lindner Andre Bernardini Ulf Brockmeier Joachim Fandrey Fritz Grunert Howard S. Oster Moshe Mittelman Mohamed El‐Tanani Markus Thiersch Edith M. Schneider Gasser Max Gassmann David Dangoor Robert J. Cuthbert Alexandra Irvine Anne Jordan Terence Lappin John Thompson Drorit Neumann 《British journal of haematology》2015,168(3):429-442
Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment. 相似文献
128.
129.
Sigrid?Carlsson Michael?Leapman Peter?Carroll Fritz?Schr?der Peter?C.?Albertsen Dragan?Ilic Michael?Barry Dominick?L.?Frosch Andrew?VickersEmail author 《BMC medicine》2015,13(1):288
Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening. 相似文献
130.
Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
下载免费PDF全文
![点击此处可从《Genes, chromosomes & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eike Burandt Melanie Schreiber Alexander Stein Sarah Minner Till S. Clauditz Carsten Bokemeyer Fritz Jänicke Margit Fisch Jakob R. Izbicki Rainald Knecht Guido Sauter Phillip R. Stahl 《Genes, chromosomes & cancer》2014,53(3):228-239
In cancer therapy, the number of drugs targeting cells with characteristic molecular aberrations is continuously rising. However, application of these new drugs still is limited to a few tumor entities. The aim of this study was to test the concept of routinely identifying all possible cancer patients who might eventually benefit from targeted therapy. Therefore, all malignant tumors routinely submitted to our Institute of Pathology over a period of 4 months were brought into a tissue microarray format. Using “in situ” methods, tumors were analyzed for HER2, EGFR, and KIT status as examples for potential therapeutic target genes. In positive cases, target heterogeneity was excluded by analyzing all available large sections. Outside of tumor entities for which targeted drugs are already approved, the study revealed six tumors with homogeneously distributed HER2 overexpression/amplification (bladder, esophageal and colorectal) and seven tumors with homogeneous EGFR amplification (vulvar, ovarian, breast, esophageal and laryngeal, and adenocarcinoma of unknown primary). A total of 151 tumors showed KIT overexpression but none of seven sequenced cases showed KIT mutations. We furthermore report on a 69‐year‐old patient with homogeneously HER2‐amplified metastatic colorectal cancer who is successfully treated by trastuzumab monotherapy. This study demonstrates that tissue microarray based screening for therapeutic target genes in tumors outside established indications represents a feasible approach suitable for routine application. The successful treatment of one patient with homogeneously HER2 positive metastatic colorectal cancer argues for the clinical utility of this approach at least in carefully selected, homogeneous cancers. © 2013 Wiley Periodicals, Inc. 相似文献